Ambryon Biosciences

5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)

Neelapu et al. (2023). Blood·Citations: 243Research

Axicabtagene ciloleucel (axi-cel) CAR T cells produced durable responses in refractory large B-cell lymphoma at 2 years, but longer-term outcomes were unreported. This 5-year ZUMA-1 analysis found a 42.6% overall survival rate. Eighty-three percent of 101 patients responded and 31% remained in response.

Key findings

  • Axi-cel gives an 83% objective response rate and 58% complete response rate in 101 patients, with 31% still in response at a median 63.1 months of follow-up.

  • Estimated 5-year overall survival is 42.6% (median 25.8 months), rising to 64.4% among patients who achieved a complete response.

  • Patients without an event-free survival event by 12 months have 90.9% 5-year overall survival versus 5.3% with one; at 24 months the figures are 92.3% versus 11.3%.

  • No new axi-cel-related serious adverse events or secondary malignancies appear after 2 years; cytokine release syndrome occurs in 93% (11% grade 3+) and neurologic events in 64% (30% grade 3+).

  • 91% (21 of 23) of evaluable patients in response at 3 years show polyclonal B-cell recovery (median immunoglobulin κ:λ ratio 1.6), so lasting B-cell aplasia is not required.

Author abstract

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we assessed outcomes in ZUMA-1 after 5 years of follow-up. Eligible adults received lymphodepleting chemotherapy followed by axi-cel (2 × 106 cells per kg). Investigator-assessed response, survival, safety, and pharmacokinetics were assessed in patients who had received treatment. The objective response rate in these 101 patients was 83% (58% complete response rate); with a median follow-up of 63.1 months, responses were ongoing in 31% of patients at data cutoff. Median overall survival (OS) was 25.8 months, and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91% of patients. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. This trial was registered at ClinicalTrials.gov, as #NCT02348216.

Identifiers & revision